|
市場調査レポート
商品コード
1309565
植物性原薬(API)の世界市場規模、シェア、産業動向分析レポート:最終用途別、分子タイプ別、地域別展望と予測、2023年~2030年Global Plant-based API Market Size, Share & Industry Trends Analysis Report By End-use (Pharmaceuticals, Nutraceuticals, and Herbal Based Industries & Others), By Molecule Type, By Regional Outlook and Forecast, 2023 - 2030 |
||||||
|
植物性原薬(API)の世界市場規模、シェア、産業動向分析レポート:最終用途別、分子タイプ別、地域別展望と予測、2023年~2030年 |
出版日: 2023年06月30日
発行: KBV Research
ページ情報: 英文 174 Pages
納期: 即納可能
![]() |
植物性原薬(API)市場規模は2030年までに426億米ドルに達し、予測期間中にCAGR 5.8%の市場成長率で上昇すると予測されます。
持続可能で自然な製品に対する消費者の欲求の高まりにより、植物由来のAPIに対する需要が増加しています。人々が使用するものが環境に与える影響は、多くの顧客にとって関心が高まっており、持続可能で自然な代替品への関心が高まっています。その結果、数多くの植物由来の医薬品が開発されています。市場の成長を後押しする主な要因のひとつは、各国政府によるヘルスケア産業への投資件数と規模の増加です。
爆発的な経済成長と医療費上昇の結果、質の高いヘルスケアへのアクセスが拡大する新興国が増えると予想されています。ヘルスケア産業への支出が増加した結果、市場は拡大しています。多くの原薬メーカーは、特に重要な医薬品のサプライチェーンにおいて、COVID以前の取り組みに戻りつつあります。大手製薬会社は新しいビジネスモデルを採用し、国ごとのKPI(重要業績評価指標)に基づくソリューションを提供しています。多くの国で研究開発が活発化した結果、植物由来のような新しい原薬の技術革新が進みました。そのため、パンデミックは市場に若干プラスの影響を与えました。
しかし、植物性原薬(API)を取り巻く規制環境は予断を許さないです。生薬研究に対する規制要件の充足に大きな隔たりがあることが、生薬規制の問題を悪化させています。生薬の有効性と安全性を立証するための科学的根拠が不十分です。したがって、これらすべての要素が市場の成長を妨げています。
分子タイプの展望
分子タイプに基づき、市場はアルカロイド、アントシアニン、フラボノイド、フェノール酸、テルペノイド、リグニン&スチルベン、その他に分類されます。テルペノイドセグメントは、2022年の市場でかなりの成長率を確保しました。テルペノイドの化学療法および治療上の利点が、このセグメントの拡大の原因であると考えられています。テルペノイドには、がんを含むさまざまな病気の予防や治療に役立つ特性があることが証明されています。これらの特性には、抗菌性、抗真菌性、抗寄生虫性、抗アレルギー性、抗ウイルス性、免疫調節性、鎮痙性、抗炎症性、抗高血糖性などが含まれます。
最終用途の展望
最終用途別では、市場は医薬品、栄養補助食品、ハーブベース産業、その他に分類されます。医薬品セグメントは2022年の市場で最大の収益シェアを記録しました。同分野の成長は、慢性疾患の罹患率の上昇と最先端の治療に対する市場のニーズの高まりによるものと考えられます。薬剤やワクチンの生産に遺伝子組み換え作物を使用することで、薬剤を低コストで提供できるようになったことは、重要な進歩のひとつです。このような医薬品の供給・流通における重要な利害関係者がより重視するようになるにつれて、患者がより迅速に医薬品を入手できるようになる植物由来の医薬品の可能性も拡大すると予想されます。
地域別展望
地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。北米セグメントは、2022年の市場において最大の収益シェアを獲得しました。老人人口の増加と国民の健康意識の高まりが、この地域の市場拡大に寄与しています。米国国勢調査局によると、2020年には米国の1歳以上の人口は5,580万人で、総人口の16.8%を占めています。栄養補助食品は慢性病を予防できるという考えが広まっているため、この地域は強い普及率と消費率を示しています。老化プロセスを遅らせることは、健康増進と慢性疾患の予防に役立ちます。
List of Figures
The Global Plant-based API Market size is expected to reach $42.6 billion by 2030, rising at a market growth of 5.8% CAGR during the forecast period.
The Plant-based API are majorly utilized in Pharmaceuticals to make a variety of medications and to provide a wide range of health advantages, therefore, the pharmaceutical sector registered $ 17,322.1 million revenue in the market in 2022. As chronic conditions like cancer, heart disease, and diabetes become more prevalent, there is an increasing demand for innovative and efficient therapies. The major causes of death in the United States, according to the CDC in 2022, were chronic diseases like diabetes, cancer, and heart disease. The country's $4.1 trillion in average healthcare costs per year are also largely attributable to them.
Similarly, according to the Australian Government, in 2020-21, one or more chronic illnesses were predicted to affect nearly half of Australians (11.6 million people or 47%). Therefore, the increasing chronic disease burden will aid in expanding the market. Some of the factors impacting the market are growing demand for sustainable and natural medicines, rise in healthcare industry investment levels, and issues like quality control, standardization, and sustainability of plant-based API.
Due to the rising consumer desire for sustainable and natural products, the demand for plant-based APIs is increasing. The environmental impact of what people use is becoming a growing concern for many customers, who are increasingly turning to sustainable and natural alternatives. As a result, numerous plant-based medications have been developed. One of the key factors boosting the market's growth is the increasing number and size of investments made in the healthcare industry by governments of different countries.
More emerging nations are anticipated to have expanded access to quality healthcare as a result of their explosive economic growth and rising healthcare costs. The market is growing as a result of rising healthcare industry spending. Many producers of APIs were returning to their pre-COVID initiatives, notably in the supply chain for vital medicines. Leading pharmaceutical companies are embracing new business models and providing solutions based on KPIs or key performance indicators per nation. Increased R&D in many nations resulted in the innovation of new APIs like plant-based. Therefore, the pandemic had a slightly positive impact on the market.
However, the regulatory environment surrounding plant-based APIs is unpredictable. A significant gap in fulfilling regulatory requirements for herbal medication research exacerbates the issue of herbal drug regulation. To establish the efficacy and safety of herbal medicines, there is inadequate scientific evidence. Hence, all these elements are hampering the growth of the market.
Molecule Type Outlook
Based on molecule type, the market is characterized into alkaloids, anthocyanin, flavonoids, phenolic acids, terpenoids, lignin & stilbenes, and others. The terpenoids segment procured a considerable growth rate in the market in 2022. The chemotherapeutic as well as therapeutic benefits of terpenoids are thought to be responsible for the segment's expansion. Terpenoids have been proven to have properties that make them beneficial in the prevention and treatment of a wide range of illnesses, including cancer. These properties include those that are antibacterial, antifungal, antiparasitic, antiallergenic, antiviral, immunomodulatory, antispasmodic, anti-inflammatory, and antihyperglycemic.
End Use Outlook
On the basis of end-use, the market is classified into pharmaceuticals, nutraceuticals, herbal based industries, and others. The pharmaceuticals segment recorded the largest revenue share in the market in 2022. The growth of the segment may be due to the rising incidence of chronic diseases and the market's growing need for cutting-edge treatments. The use of genetically engineered crops to produce drugs and vaccines, which helps provide medications at a reduced cost, is one of the significant advancements. As important stakeholders in the supply & distribution of such pharmaceuticals place a greater emphasis on them, the potential for plant-based pharmaceuticals to give patients speedier access to drugs is also expected to grow.
Regional Outlook
Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment garnered the maximum revenue share in the market in 2022. The increase in the geriatric population and the increased health consciousness among the populace are both credited with the market expansion in this region. According to the United States Census Bureau, in 2020, there were 55.8 million people over the age of one in the United States or 16.8% of the total population. Due to the widespread belief that nutraceuticals can prevent chronic diseases, the region exhibits strong adoption and consumption rates. Slowing down the aging process helps to promote health and prevent chronic diseases.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BASF SE, Evonik Industries AG (RAG-Stiftung), Cargill, Incorporated, Roquette Freres SA, Arboris, LLC, Centroflora Group, Kothari Phytochemicals & Industries Ltd., Brains Bioceutical Corp., Indo Phytochem Pharmaceuticals and HimPharm.
Market Segments covered in the Report:
By End-use
By Molecule Type
By Geography
Companies Profiled
Unique Offerings from KBV Research